Mostrando 3 resultados de: 3
Filtros aplicados
Origen
scopus(3)
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
ArticleAbstract: Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shownPalabras claves:immune checkpoint inhibitor, immunotherapy, lung cancer, Non-small cell lung cancer, VaccineAutores:Attwood K., Cedeno C., Cinquino A., Dai T., Dozier A., Dy G.K., Ernstoff M., Evans R., Fisher D.T., Fountzilas C., Groman A., Hutson A., Johnson C., Lage Davila A., Lee K., Leon K., Luaces P.L.o., Mazorra Z., Mesa C., Muhitch J., Opyrchal M., Puzanov I., Reid M., Saavedra Hernández D., Santos-Morales O., Tania Crombet, Wallace P.K.Fuentes:scopusA novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
ArticleAbstract: Background: There is evidence of a relationship between epidermal growth factor (EGF) and tumor cellPalabras claves:cancer vaccine, Epidermal growth factorAutores:Catala M., González G., Gonzalez Y.S., Guillén-Nieto G.E., Hernández J.C., Lage Davila A., Marinello P., Mirabal V., Tania CrombetFuentes:scopusTargeting epidermal growth factor receptor signaling: Early results and future trends in oncology
ReviewAbstract: Epidermal growth factor receptor (EGFR), a member of a family of membrane receptors with tyrosine kiPalabras claves:cancer therapy, Cancer Vaccines, clinical trials, Epidermal growth factor, Epidermal growth factor receptor, monoclonal antibodies, Tyrosine kinasesAutores:González G., Lage Davila A., Tania CrombetFuentes:scopus